Join our daily newsletter At The Bell to receive exclusive market insights
- Zelira Therapeutics (ZLD) promotes Greg Blake to the role of Executive Director
- Mr Blake joined the company in 2020 and has been serving as Vice President, Global Head of Commercial and Partnering
- After more than 20 years working in the healthcare industry, he has commercial and operational leadership experience both within Australia and internationally
- During his career, Mr Blake has led the strategic development and commercialisation of a number of products across a range of therapeutic categories
- ZLD shares resumed trade today, down 15.3 per cent to $1 at 3:20 pm AEDT
Developer of clinically validated cannabis medicines, Zelira Therapeutics (ZLD) has promoted Greg Blake to the role of Executive Director.
Mr Blake joined the company in 2020 and has been serving as Vice President, Global Head of Commercial and Partnering.
After more than 20 years working in the healthcare industry, ZLD said the new Executive Director brings extensive commercial and operational leadership experience both within Australia and internationally.
During his career, Mr Blake has led the strategic development and commercialisation of a number of products across a range of therapeutic categories.
He was previously General Manager of Rhythm Biosciences (RHY) where he led the company through the establishment of the pre-launch critical pathway and commercialisation planning for both domestic and international markets.
Moreover, as Marketing Lead for Mundipharma International, Mr Blake led 26 European countries through the pre-launch and launch phases for a novel pain medication.
The promotion comes with a $245,000 per year salary and $25,725 superannuation.
The company’s shares were placed in a trading halt on February 17 ahead of today’s announcement.
Shares resumed trade today and were down 15.3 per cent to $1 at 3:20 pm AEDT.
